Randomized Trial of Interleukin-2 (IL-2) as Early Consolidation Following Marrow Ablative Therapy with Stem Cell Rescue for Metastatic Breast Cancer
Abstract
Marrow ablative doses of chemotherapy followed by stem cell rescue (MAT/SR) produce a high frequency of objective responses in patients with metastatic breast cancer, with up to 40-50% complete responses. Unfortunately, responses tend to be short-lived. Interleukin-2 (IL-2) can activate lymphocytes to kill multi- drug resistant cancer cells. Our phase I data established that a single course of low-dose IL-2 (1.6 million IU/m2/day as a continuous i.v. infusion for 18 days) as consolidation treatment to patients with metastatic breast cancer early after MAT/SR. Seven patients (60%) remain in complete remission at a median of 435 days (range: 224 - 720 days) post stem cell transplantation. Since this trial was designed, substantial changes have taken place in breast cancer treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2001
- Accession Number
- ADA396717
Entities
People
- Wolfram E. Samlowski
Organizations
- University of Utah